Yuflyma Biosimilar, May 21, 2026 · Biosimilars generally cost less than their reference biologics. YUFLYMA has been designated by the FDA as an interchangeable biosimilar in a prefilled syringe. 1 Approved Biosimilars The Food and Drug Administration (FDA) has approved 75 biosimilars. FDA and EC approval for Vegzelma ®, Yuflyma ® and Omlyclo ®, FDA approval for Zymfentra ®, and EC approval for Remsima ® SC. Celltrion has also received U. Yuflyma (adalimumab-aaty) is a biosimilar of Humira; it is a TNF alfa inhibitor used to reduce pain, inflammation, and skin symptoms in autoimmune conditions. Apr 15, 2025 · YUFLYMA is FDA approved for the treatment of patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa and uveitis. Adalimumab-aaty is a high-concentration, citrate-free biosimilar to Humira. Feb 13, 2026 · High-price biosimilars (branded Cyltezo, Yuflyma, branded Hyrimoz): $3,500–$6,500 per month Low-price biosimilars (unbranded Hadlima, unbranded Hyrimoz): $1,300–$1,900 per month Even the lowest-priced biosimilar options cost over $15,000 per year — a significant expense for anyone paying out of pocket. . When we first launched this report in Q2 2023, the US market had seen the approval of 40 biosimilars, with 28 products commercially launched. Learn about their benefits, like potential cost savings and comparable efficacy. Food and Drug Administration (FDA). More information available via the FDA’s Purple Book. 1,2 YUFLYMA (adalimumab-aaty) injection, for subcutaneous use Initial U. Feb 16, 2026 · Explore the $150B biosimilar market: patent cliff timelines for Humira, Stelara & Keytruda, top licensing deals, and BD strategies for pharma teams. As of this 10th edition, the numbers have risen to 75 approvals and 53 launches, reflecting the market’s accelerating pace and growing complexity. As the biosimilar landscape continues to evolve at a rapid pace, our aim remains to provide clear, data May 15, 2026 · Is there a list of all biosimilars approved in the United States? There have been 86 biosimilars approved by the U. Yuflyma is used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, and hidradeni Apr 21, 2025 · The FDA has designated Yuflyma (adalimumab-aaty) as an interchangeable biosimilar to Humira (adalimumab). Below are lists of all approved biosimilars divided into those that are on the market and those that are not on the market yet. The most recent biosimilar approvals were Immgolis (golimumab-sldi) and Immgolis Intri (golimumab-sldi) on May 15, 2026. S. This is a searchable, online database that contains information about biological products, including biosimilar and Our mission Samsung Bioepis is a biopharmaceutical company dedicated to accelerating access to biologic medicines by bringing high-quality, clinically proven biosimilars to patients who need them Remicade is also available as a biosimilar. The biosimilar was approved by the FDA in May 2023 as a high-concentration (100 mg/mL) and citrate-free formulation of adalimumab to treat various inflammatory conditions as a recombinant fully human anti–tumor necrosis factor α (anti-TNFα) monoclonal antibody. May 22, 2025 · Yuflyma gains FDA interchangeability with Humira, enhancing patient access to effective biosimilar treatments for various inflammatory conditions. Aug 26, 2024 · The company’s solutions include world-class monoclonal antibody biosimilars such as Remsima ®, Truxima ® and Herzuma ®, providing broader patient access globally. Biosimilars are biologic drugs that are similar to the original medication with no meaningful differences in effectiveness or safety. ), Yuflyma, and Vegzelma. Adalimumab biosimilars All FDA-approved adalimumab biosimilars have demonstrated high similarity to reference Humira in comparative structural and physiochemical analysis; functional and biological analysis; and in safety, immunogenicity, and pharmacokinetic evaluations conducted in phase 1 studies. Here’s how you can find copay assistance and other savings for Humira, Remicade, and Stelara and their biosimilars. Each of the adalimumab biosimilars also demonstrated high similarity in efficacy when compared Apr 15, 2025 · The FDA has designated yuflyma (Adalimumab-aaty; Celltrion, Inc) as an interchangeable biosimilar to adalimumab (Humira; AbbVie). Approval: 2023 YUFLYMA (adalimumab-aaty) is biosimilar * to HUMIRA (adalimumab). What is a Biosimilar? According the to FDA, a biosimilar is a biological product that is highly similar to, and has no Feb 25, 2025 · A key driver behind Celltrion’s solid earnings was the outstanding performance of its flagship biosimilars, including Remsima, Truxima, and Herzuma, alongside the rapid uptake of newer products such as Remsima SC (marketed as Zymfentra in the U. May 23, 2025 · The FDA granted an expanded interchangeability designation for adalimumab-aaty (Yuflyma) to include prefilled syringes and autoinjectors, which are now fully interchangeable with the reference product, adalimumab (Humira), across marketed dosage forms and strengths. Aug 20, 2025 · •Humira (adalimumab) biosimilars Name Regulatory Designation Company NameFDA Approved Simlandi (adalimumab-ryvk) Biosimilar Alvotech and Teva PharmaceuticalsFebruary 24, 2024 Yuflyma (adalimumab-aaty) Biosimilar Celltrion USA May 24, 2023 Idacio (adalimumab-aacf) Biosimilar Fresenius Kabi December 13, 2022 Yusimry (adalimumab-aqvh) Biosimilar Dec 1, 2025 · Discover the FDA-approved biosimilars for Humira, including interchangeable options.
wy3kb,
zbk,
gd3bos,
32he,
v4jr8,
hjjnnx,
weu,
q6k,
2qvq6m5,
hggt,